Article Information
History
- January 28, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Dr Rahul Krishnatry, Principal Investigator1,*,
- Dr Vikram Gota, Co-Principal Investigator2,
- Dr Debanjan Chakraborty, Co-investigator1,
- Dr Vikas Ostwal, Co-investigator4,
- Mrs. Sadhana Kannan, Co-investigator3,
- Ms Pallavi Rane, Co-investigator3,
- Dr Shivakumar Gudi, Co-investigator1,
- Dr Mufaddal Kazi, Co-investigator5,
- Dr Anant Ramaswamy, Co-investigator4,
- Dr Prabhat Bhargava, Co-investigator4,
- Dr Purvi Haria, Co-investigator6,
- Dr Suman K Ankathi, Co-investigator6,
- Dr Munita Bal, Co-investigator7,
- Dr Mukta Ramadwar, Co-investigator7,
- Dr Ashwin DeSouza, Co-investigator5,
- Dr Avnish Saklani, Co-investigator5 and
- Dr Reena Engineer, Co-investigator1
- 1Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
- 2Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India
- 3Department of Epidemiology and Clinical Trials Unit, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India
- 4Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
- 5Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
- 6Department of Radiology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
- 7Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
- ↵*Correspondence
- Dr Rahul Krishnatry MD, DNB Professor, Homi Bhabha National Institute (HBNI), Department of Radiation Oncology, Tata Memorial Centre, Dr Ernest Borges Marg, Mumbai, Maharashtra 400012, India., Adress: Room No 1125, 11th floor, HBB Block., Email: krishnatry{at}gmail.com, krishnatryr{at}tmc.gov.in
Posted January 28, 2024.
Phase II Randomized Study of Short Course Radiotherapy Total Neo-adjuvant Therapy with or without Chlorophyllin in Reducing the Incidence of >/=Grade 2 Acute Toxicity in Advanced Rectal Cancer patients Suitable for Wait and Watch
